SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw its shares climb 12.3% on Friday, closing at $13.19. The move drew attention to a significant discrepancy in the company's market capitalization, which stands at approximately $319 million less when calculated using the most recent share count versus live market data.
Market Cap Discrepancy
Based on the company's latest reported share count of 196.6 million shares as of June 2, the implied equity value at Friday's closing price is roughly $2.594 billion. However, current market feeds show a market capitalization of around $2.275 billion, a figure that aligns with the weighted average share count of 172.5 million shares used in the first quarter. This gap of about $319 million has raised questions among investors about the true valuation of the company.
REGAL Trial Progress
SELLAS is primarily focused on the development of its lead candidate, galinpepimut-S, for the treatment of acute myeloid leukemia (AML). The REGAL trial, a Phase 3 study, is a critical catalyst for the company. As of the most recent update, 78 out of the required 80 events had occurred, and the trial remains blinded. The 80th event will trigger database lock, data review, analysis, and subsequent unblinding. Chief Executive Angelos Stergiou described the upcoming results as an important milestone for the company.
Share Issuance and Cash Position
The number of outstanding shares has increased significantly over the past year, rising by 97% from May 2025 to June 2026. This dilution has been driven by warrant exercises and an at-the-market (ATM) offering program. As of March, SELLAS held $107.1 million in cash, with an additional $28.7 million coming from warrant proceeds. The company's ability to fund operations and trials remains a key focus for investors.
Comparison with Peers
SELLAS's current valuation stands 29% higher than Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) and is 2.7 times higher than Kura Oncology, Inc. (NASDAQ:KURA). Both rivals have FDA-approved therapies for AML, while SELLAS remains in the clinical development stage. This comparison underscores the market's high expectations for the REGAL trial outcomes.
Recent Trading Activity
Friday's gain came after two days of declines, with shares falling 4.5% on Wednesday and 8.1% on Thursday. Despite the volatility, the stock finished the week 3.4% higher compared to the previous Friday's close. Trading volume was 11.3 million shares, exceeding the 65-day average by 23%. The significant price move on Friday added approximately $283 million to the company's market cap, which is 2.1 times the cash held in March combined with gross warrant proceeds.
Outlook and Risks
Investors are now awaiting the 80th event in the REGAL trial, which could come at any time. While the market is optimistic, there are risks that the trial may yield disappointing or ambiguous outcomes, or that results could be delayed. Additionally, further dilution from warrant exercises or the $150 million ATM program could impact shareholder value. Standard trading resumes on Monday, July 20, at 9:30 a.m. EDT.
